Depletion of nonmalignant lymphocytes during venetoclax-obinutuzumab treatment. Lymphocyte analysis in PB of patients at baseline (n = 36), after preinduction with obinutuzumab (n = 5), and after 1 year of treatment with venetoclax-obinutuzumab (n = 11) by flow cytometry. Absolute number of B cells (A) and CD4⁺ and CD8⁺ T cells (B) in PB. (C) Absolute number of NK (CD56^bright and CD16⁺) cells in PB (baseline, n = 20). (D) Ratio of CD56^bright (CD56^brightCD16⁻)/CD56^dim (CD56^dimCD16⁺) cells (baseline, n = 6). Horizontal lines indicate reference values. *P < .05, **P < .01, 1-way ANOVA followed by Sidak’s multiple-comparisons test.